Custom monoclonal antibody development for immune checkpoint targets enables precise modulation of immune responses in cancer research. Using technologies like hybridoma and phage display, scientists generate high-affinity antibodies against PD-1, CTLA-4, and other checkpoint proteins. These tailored antibodies support therapeutic innovation, offering tools for blocking inhibitory signals and enhancing T cell activation in tumor microenvironments.
